VANCOUVER, Oct. 11 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has received CE Mark approval to begin marketing the Quill(TM) Self-Retaining System (SRS) MONODERM(TM) sutures in Europe.
This CE Mark approval follows Angiotech's recent announcement in August 2007 that it had received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing the Quill(TM) SRS MONODERM(TM) product line in the United States.
"We are pleased with our accelerated pace in building out our North American Quill(TM) sales force, and we are making good progress in assembling a corresponding team in Europe to support this key catalyst product for Angiotech," said Chris Dennis, Senior Vice President, Global Sales & Marketing for Angiotech.
"With these approvals, we can now focus on making the Quill(TM) SRS product line widely available in the US, Europe, Asia, and Latin America. Angiotech will continue to expand the Quill(TM) SRS product line to cover multiple procedures for wound closure and tissue approximation," added Mr. Dennis.
Quill(TM) SRS MONODERM(TM) sutures, which are made from a rapidly resorbing polymer, are intended primarily for superficial wound closure applications and indicated for soft tissue approximation where use of an absorbable suture is appropriate. It is anticipated that the Quill(TM) SRS MONODERM(TM) sutures will be available in various lengths and needle configurations using three different diameters (USP sizes 0, 2-0 and 3-0).
Angiotech expects to exhibit and introduce the Quill(TM) SRS product
line at the Annual Meeting of the American Society of
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved